Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1452 Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade

Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Borget I,

Keywords: stage IV, pancreatic neuroendocrine tumor, prognosis, survival,

#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting

Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Del Prete M

Authors: Del Prete M, Malka L, Borget I, Berdelou A, Boige V,

Keywords: Pancreatic Neuroendocrine Tumor, Everolimus, Safety,

#1225 Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gianoncelli L, Guigay J, Caramella C, Borget I, Mir O,

Keywords: lung carcinoid, everolimus, mTOR inhibitor,

#282 Characteristics of Patients with Well-differentiated Metastatic Lung Neuroendocrine Tumors

Introduction: Characteristics of well-differentiated lung neuroendocrine tumors (WDLNET) are poorly characterized at the metastatic stage.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Chougnet C, Guigay J, Borget I, Leboulleux S, Duvillard P,

Keywords: lung NET, metastases, somatostatin analog, somatostatin recpetor scintigraphy ,